Financial Data and Key Metrics Changes - In 2025, organic revenue increased by 8%, reported operating income grew by 31%, and reported net income rose by 82% [7][8] - Operating income margin improved to 11.3%, within the midterm target band of 10%-14% [8][16] - Earnings per share grew by 44%, reflecting both earnings strength and the impact of the accelerated share buyback program [8][13] - Net leverage improved to 2.5x, down from 3.4x at the end of 2022 [11] Business Line Data and Key Metrics Changes - Care delivery segment revenue grew nearly 2% at constant currency, with organic revenue growth reaching almost 5% [17] - Value-based care segment saw organic revenue growth of 34%, driven by contract expansion and strong member months growth [9][17] - Care enablement revenue grew by 2% at constant currency, with operating income increasing by 33% at constant currency [18] Market Data and Key Metrics Changes - Flat same-market treatment growth in the U.S. was observed, with expectations of a 2%+ recovery due to quality initiatives [8][9] - The introduction of the 5008X machine in the U.S. is expected to improve treatment quality and operational efficiency [14][15] Company Strategy and Development Direction - The company introduced the FME Reignite strategy, focusing on operational excellence, growth and innovation, and cultural enhancement [4][5] - The FME25 transformation program exceeded its sustainable savings target, achieving EUR 804 million by year-end 2025 [6][12] - The company aims to maintain enhanced profitability while investing for future value creation, targeting a compound annual growth rate of 3%-7% through 2028 [20][22] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing inflationary pressures and regulatory headwinds as significant challenges for 2026 [25][29] - The company expects flat revenue growth in 2026, primarily due to changes in value-based care's risk contracting [19] - Management is confident in returning to a 2%+ growth in same-market treatment once mortality levels normalize [33][36] Other Important Information - The company generated EUR 2.7 billion in operating cash flow in 2025, demonstrating strong cash performance [12] - A dividend of EUR 1.49 is proposed for 2025, representing a 3% increase from 2024 [13] Q&A Session Summary Question: What is the biggest drag on the business: inflationary pressures or costs related to the new dialysis device launch? - Management indicated that both factors are significant, with an investment of EUR 100 million-EUR 150 million for the HDF launch and operational costs [25][29] Question: Can you estimate the cost for the large-scale 5008X launch in the U.S.? - Management estimated upfront costs for training and implementation at EUR 100 million-EUR 150 million, with half attributed to HDF [31][32] Question: When do you expect to see a turnaround in U.S. treatment volumes? - Management projected flat growth for 2026 but expressed confidence in returning to 2%+ growth once mortality levels normalize [33][34] Question: What is your perspective on the latest U.S. tariff changes? - Management noted that tariffs were immaterial in 2025 but expect some impact in 2026, monitoring developments closely [38][39] Question: In which locations in Germany is Fresenius Medical Care planning to invest? - Management highlighted investments in manufacturing plants in Schweinfurt and Sindelfingen, which are core to their production [40][41]